Search Results
Oct 29, 2025, 11:09 ET I-MAB (Nasdaq: IMAB)正式更名為新橋生物（NovaBridge Biosciences；Nasdaq: NBP），股票交易將於 2025 年 10 月 30 日正式生效，新品牌標誌著其向全球生物科技平台型公司的戰略轉型。
Biosciences，下稱「新橋生物」或「公司」）今日宣布，公司已完成名稱變更，由「I-Mab」正式更名為「新橋生物」。此項更名決議已獲得公司於2025年10月24日召開的特別股東大會高票通過，並獲董事會批准。自2025年10月30日開盤起，公司美國存托股份（ADS）將正式啟用新公司名稱及新股票代碼「NBP」（Nasdaq: NBP），取代現有代碼「IMAB」（Nasdaq: IMAB）。 公司同步上線全新品牌及官網（www.novabridge.com），標誌著向全球生物科技平台戰略轉型邁出關鍵一步，持續致力於加速創新療法惠及全球患者。
More news about: 新桥生物
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), and I-Mab (NASDAQ: IMAB).
More news about: Equity Insider
Oct 07, 2025, 08:00 ET Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
targets[5]. Clinical-stage developers advancing these differentiated mechanisms include GT Biopharma, Inc. (NASDAQ: GTBP), I-Mab (NASDAQ: IMAB), enGene Holdings Inc. (NASDAQ: ENGN), Onconetix, Inc. (NASDAQ: ONCO), and Nanobiotix S.A. (NASDAQ: NBTX).
More news about: Equity Insider